Back to News
Market Impact: 0.22
BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln
Source: Nasdaq
Healthcare & BiotechM&A & RestructuringPrivate Markets & Venture
BoomRay Pharmaceuticals signed an exclusive global license agreement with Novartis Pharma for an undisclosed preclinical radioligand-therapy asset. The deal expands BoomRay's early-stage oncology pipeline, though financial terms, development milestones and the specific asset were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVS0.35
More News
- Halozyme Therapeutics completes $1.5 billion convertible notes offering
- Why is Celldex Therapeutics stock sliding today?
- Paramount will need to release way more movies to make this merger work
- Anthropic in talks to lease 1 gigawatt from Stream Data Centers- The Information
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder